Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) ...
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...
Cema-cel demonstrated durable responses in relapsed/refractory large B-cell lymphoma, with high overall and complete response rates comparable to autologous CAR-T therapies. The safety profile of cema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results